Cargando…

Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients

INTRODUCTION: Gut microbiota has been implicated in the pharmacological activities of many natural products. As an effective hypolipidemic agent, berberine (BBR)’s clinical application is greatly impeded by the obvious inter-individual response variation. To date, little evidence exists on the causa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Chongming, Zhao, Ying, Zhang, Yingying, Yang, Yanan, Su, Wenquan, Yang, Yuanyuan, Sun, Le, Zhang, Fang, Yu, Jiaqi, Wang, Yaoxian, Guo, Peng, Zhu, Baoli, Wu, Shengxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039652/
https://www.ncbi.nlm.nih.gov/pubmed/35499044
http://dx.doi.org/10.1016/j.jare.2021.07.011
_version_ 1784694174685069312
author Wu, Chongming
Zhao, Ying
Zhang, Yingying
Yang, Yanan
Su, Wenquan
Yang, Yuanyuan
Sun, Le
Zhang, Fang
Yu, Jiaqi
Wang, Yaoxian
Guo, Peng
Zhu, Baoli
Wu, Shengxian
author_facet Wu, Chongming
Zhao, Ying
Zhang, Yingying
Yang, Yanan
Su, Wenquan
Yang, Yuanyuan
Sun, Le
Zhang, Fang
Yu, Jiaqi
Wang, Yaoxian
Guo, Peng
Zhu, Baoli
Wu, Shengxian
author_sort Wu, Chongming
collection PubMed
description INTRODUCTION: Gut microbiota has been implicated in the pharmacological activities of many natural products. As an effective hypolipidemic agent, berberine (BBR)’s clinical application is greatly impeded by the obvious inter-individual response variation. To date, little evidence exists on the causality between gut microbes and its therapeutic effects, and the linkage of bacteria alterations to the inter-individual response variation. OBJECTIVES: This study aims to confirm the causal role of the gut microbiota in BBR’s anti-hyperlipidemic effect and identify key bacteria that can predict its effectiveness. METHODS: The correlation between gut microbiota and BBR’s inter-individual response variation was studied in hyperlipidemic patients. The causal role of gut microbes in BBR’s anti-hyperlipidemic effects was subsequently assessed by altered administration routes, co-treatment with antibiotics, fecal microbiota transplantation, and metagenomic analysis. RESULTS: Three-month clinical study showed that BBR was effectively to decrease serum lipids but displayed an obvious response variation. The cholesterol-lowering but not triglyceride-decreasing effect of BBR was closely related to its modulation on gut microbiota. Interestingly, the baseline levels of Alistipes and Blautia could accurately predict its anti-hypercholesterolemic efficiency in the following treatment. Causality experiments in mice further confirmed that the gut microbiome is both necessary and sufficient to mediate the lipid-lowering effect of BBR. The absence of Blautia substantially abolished BBR's cholesterol-decreasing efficacy. CONCLUSION: The gut microbiota is necessary and sufficient for BBR’s hyperlipidemia-ameliorating effect. The baseline composition of gut microbes can be an effective predictor for its pharmacotherapeutic efficacy, providing a novel way to achieve personalized therapy.
format Online
Article
Text
id pubmed-9039652
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90396522022-04-27 Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients Wu, Chongming Zhao, Ying Zhang, Yingying Yang, Yanan Su, Wenquan Yang, Yuanyuan Sun, Le Zhang, Fang Yu, Jiaqi Wang, Yaoxian Guo, Peng Zhu, Baoli Wu, Shengxian J Adv Res Medicine INTRODUCTION: Gut microbiota has been implicated in the pharmacological activities of many natural products. As an effective hypolipidemic agent, berberine (BBR)’s clinical application is greatly impeded by the obvious inter-individual response variation. To date, little evidence exists on the causality between gut microbes and its therapeutic effects, and the linkage of bacteria alterations to the inter-individual response variation. OBJECTIVES: This study aims to confirm the causal role of the gut microbiota in BBR’s anti-hyperlipidemic effect and identify key bacteria that can predict its effectiveness. METHODS: The correlation between gut microbiota and BBR’s inter-individual response variation was studied in hyperlipidemic patients. The causal role of gut microbes in BBR’s anti-hyperlipidemic effects was subsequently assessed by altered administration routes, co-treatment with antibiotics, fecal microbiota transplantation, and metagenomic analysis. RESULTS: Three-month clinical study showed that BBR was effectively to decrease serum lipids but displayed an obvious response variation. The cholesterol-lowering but not triglyceride-decreasing effect of BBR was closely related to its modulation on gut microbiota. Interestingly, the baseline levels of Alistipes and Blautia could accurately predict its anti-hypercholesterolemic efficiency in the following treatment. Causality experiments in mice further confirmed that the gut microbiome is both necessary and sufficient to mediate the lipid-lowering effect of BBR. The absence of Blautia substantially abolished BBR's cholesterol-decreasing efficacy. CONCLUSION: The gut microbiota is necessary and sufficient for BBR’s hyperlipidemia-ameliorating effect. The baseline composition of gut microbes can be an effective predictor for its pharmacotherapeutic efficacy, providing a novel way to achieve personalized therapy. Elsevier 2021-07-30 /pmc/articles/PMC9039652/ /pubmed/35499044 http://dx.doi.org/10.1016/j.jare.2021.07.011 Text en © 2022 The Authors. Published by Elsevier B.V. on behalf of Cairo University. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Medicine
Wu, Chongming
Zhao, Ying
Zhang, Yingying
Yang, Yanan
Su, Wenquan
Yang, Yuanyuan
Sun, Le
Zhang, Fang
Yu, Jiaqi
Wang, Yaoxian
Guo, Peng
Zhu, Baoli
Wu, Shengxian
Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients
title Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients
title_full Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients
title_fullStr Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients
title_full_unstemmed Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients
title_short Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patients
title_sort gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (bbr) and facilitates to predict bbr’s cholesterol-decreasing efficacy in patients
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039652/
https://www.ncbi.nlm.nih.gov/pubmed/35499044
http://dx.doi.org/10.1016/j.jare.2021.07.011
work_keys_str_mv AT wuchongming gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT zhaoying gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT zhangyingying gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT yangyanan gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT suwenquan gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT yangyuanyuan gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT sunle gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT zhangfang gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT yujiaqi gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT wangyaoxian gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT guopeng gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT zhubaoli gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients
AT wushengxian gutmicrobiotaspecificallymediatestheantihypercholesterolemiceffectofberberinebbrandfacilitatestopredictbbrscholesteroldecreasingefficacyinpatients